SAT0274 Retention rates of certolizumab pegol in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients: hur-bio real life results
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4649
Abstract: Background Drug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD. Objectives To evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS) and non-radiographic… read more here.
Keywords: certolizumab pegol; hur bio; nraxspa patients; rates certolizumab ... See more keywords